Akèy › Myelom miltip k ap boukante › Massachusetts › Boston
Etid klinik pou Myelom miltip k ap boukante nan Boston, MA
6 etid pou Myelom miltip k ap boukante ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Ap rekriteFaz 3
- Dana Farber / Harvard Cancer Center, Boston
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Ap rekriteFaz 3
- Tufts Medical Center, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Ap rekriteFaz 2
- Dana Farber Cancer Institute, Boston
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Ap rekriteEtid obsèvasyon
- Dana-Farber Cancer Institute, Boston
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Ap rekriteEtid obsèvasyon
- Tufts Medical Center, Boston
Etid Myelom miltip k ap boukante nan lòt vil
- New York City, NY6 etid
- Atlanta, GA5 etid
- Denver, CO3 etid
- Durham, NC3 etid
- Houston, TX3 etid
- Columbus, OH3 etid
- Salt Lake City, UT3 etid
- Edison, NJ3 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.